DRG Market Assessment reports

The treatment landscape for advanced platinumresistant ovarian cancer remains highly challenging, as conventional singleagent chemotherapies provide limited and shortlived benefit. Unlike the…

Multiple myeloma represents a complex and increasingly competitive hematologic malignancy landscape, with treatment approaches evolving rapidly across lines of therapy. While IMiDs, proteasome…

Epilepsy is a complex neurological disorder marked by recurrent seizures, affecting approximately 4.7 million people across the major markets, as reported by Clarivate Epidemiology. Given epilepsy…

The introduction of the immune checkpoint inhibitors Keytruda (Merck & Co.), Opdivo ± Yervoy, and Opdualag (Bristol Myers Squibb), as well as BRAF/MEK inhibitor combinations such as Roche /…

Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…

The treatment of multiple myeloma is becoming increasingly complex. Sanofi’s Sarclisa received a label expansion for the first-line treatment of autologous stem-cell transplantation-ineligible…

Immune checkpoint inhibitors such as Opdivo (Bristol Myers Squibb / Ono Pharmaceutical) and Keytruda (Merck & Co.) have transformed gastroesophageal cancer treatment, driving significant market…

Dravet syndrome (DS) is a rare, severe, pediatric-onset genetic epileptic encephalopathy that typically emerges within the first year of life and is marked by developmental delays and multiple…

Alzheimer’s disease (AD) affects cognition and causes neuropsychiatric symptoms (e.g., agitation, aggression, psychosis) that intensify as the disease advances. Disease-modifying therapy (DMT) is…

The multibillion-dollar NSCLC therapy market is highly dynamic, with a plethora of approved therapies but still a high unmet need. Immune checkpoint inhibitors such as Keytruda (Merck & Co.)…

Agitation affects most Alzheimer’s disease (AD) patients and comprises a constellation of disruptive symptoms for patients and their families, which may contribute to nursing home placement…

The landscape of advanced HR-positive / HER2-negative breast cancer treatment is continually evolving. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio)…